© 2021 Osprey Medical Inc. All rights reserved.
Osprey Medical, DyeVert, DyeMINISH, and Be Kind to Kidneys are registered trademarks of Osprey Medical, Inc. in the United States and other countries.
Board of Directors
Mike McCormick, President & CEO
Mike McCormick
President & CEO
Mike has more than 30 years of experience in the medical device industry and President level experience with both public and private medical device companies. Prior to Osprey Medical, he was President/CEO of Anulex Technologies, Inc., focused on supporting the healing of spinal soft tissues; President of Centerpulse Spine-Tech and was involved in the successful sale of Centerpulse Inc. to Zimmer in 2003 for US$3.2 billion. Mike also spent 10 years in sales and sales leadership positions with Boston Scientific’s Cardiovascular Division (SCIMED) and Baxter Healthcare. Mike received a BBA from the University of Texas at Austin and is an active board member at Formae, Inc.
John Erb, Non-Executive Chairman
John Erb
Non-Executive Chairman
John joined the board of the Company as an independent director and non-executive Chairman in June 2007. John has over 40 years of experience in the medical device industry. He is currently Chairman of the Board and Chief Executive Officer of CHF Solutions, Inc., a manufacturer of medical devices for the heart failure market. John previously served as Chairman of the Board for Vascular Solutions, Inc., manufacturer of medical devices for the cardiology and interventional radiology markets, which was acquired in 2017 by Teleflex, Inc. for US$1 billion. He has held numerous board positions, including CryoCath Technologies, Inc., acquired by Medtronic for US$350 million in 2008; and SenoRx, Inc., acquired by C.R. Bard for US$250 million in 2010. John has a bachelor’s degree in Business Administration from California State University, Fullerton.
Steve Brandt, Non-Executive Director
Steve Brandt
Non-Executive Director
Mr. Brandt is a senior executive with over 35 years of experience in the healthcare industry. Mr. Brandt was employed by Thoratec Corporation from November 2004 to October 2015, serving as Vice President Global Sales and Marketing, Vice President of Global Sales, and Vice President International Sales. Prior to Thoratec, Mr. Brandt was Vice President Sales & Marketing for CHF Solutions (now Nuwellis) from October 2002 to November 2004 and Vice President Global Marketing, Cardiovascular Surgery Division for St. Jude Medical from November 2000 to October 2002.
Mr. Brandt received his B.S. from Franklin Pierce College.
Sandra Lesenfants, Non-Executive Director
Sandra Lesenfants
Non-Executive Director
Sandra currently serves as the Business Leader Hospital Patient Monitoring, EVP & President, at Phillips. Previously, she served as the Vice President & General Manager of the Structural Heart Business at Medtronic.
Sandra has broad commercial strategy experience and global business management skills from the vascular businesses at Medtronic, Covidien, EV3, and Siemens Healthcare. She has led several key integrations including the acquisition of Sapheon and its VenaSeal closure system, the integration of endoVenous business from Covidien’s Vascular Therapy business into Medtronic, and the integration of the embolization sales team from Medtronic’s Neurovascular division into endoVenous.
Sandra has a biomedical computer engineering degree from the University of Technology of Compiegne Engineering Institute in France.
Neville Mitchell, Non-Executive Director
Neville Mitchell
Non-Executive Director
Neville joined the board of the Company as an independent non-executive director in July 2012 and is the Chairman of the Audit and Risk Committee. Neville was CFO and Company Secretary of Cochlear Limited from 1995 to 2017. He is a non-executive Director of Sonic Healthcare (since 2108), Fisher and Paykel Healthcare (since 2018) and Q’Biotics (since 2017) . He is a member of the Australian Board of Taxation and a director of the South East Sydney Local Health District Board. Previously he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100 and Chairman Standing Committee (Accounting and Auditing)for ASIC. Neville has a Bachelor of Commerce Degree and is a member of Chartered Accountants Australia and New Zealand.
Chris Nave, Ph.D., Non-Executive Director
Chris Nave, Ph.D.
Non-Executive Director
Dr Nave was appointed a non-executive director of the Company on 24 October 2005 and currently serves on the Audit and Risk Committee and as Chair of the Nomination and Remuneration Committee.
Dr Nave is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund. Brandon Capital Partners Pty Limited is the investment manager of various funds which have a substantial security holding in the Company.
Dr Nave is not considered to be an independent director of the Company under the ASX Corporate Governance Principles and Recommendations due to his position at a fund manager that has an association with some of the Company’s major shareholders. (Dr Nave, is a Partner of Brandon Capital Partners).
Dr Nave was previously Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. Dr Nave was also Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne.
In 2014, Dr Nave was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award, for his contribution to the industry.
Dr Nave is currently a Director of Global Kinetics Corporation, PolyActiva, OccuRx Therapeutics, QueOncology, Azura Ophthalmics and EBR Systems Inc. He has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.
Marty Emerson, Non-Executive Director
Marty Emerson
Non-Executive Director
Marty Emerson has nearly 30 years of experience in the medical device industry, including Chief Executive Officer positions with both private and public companies.
Mr Emerson has been CEO of Monteris Medical since 2016. Previously, he spent eight years as the President and Chief Executive Officer of Galil Medical, a privately-held company and leader in the cryoablation systems market, leading Galil to a successful acquisition by BTG plc. He also served as President and Chief Executive Officer of American Medical Systems (AMS), a publicly-traded urology and gynecology device company with sales of over $500 million. Marty has also held various management positions, both domestic and international, with Boston Scientific Corporation and Baxter International. He currently serves on the Board of Directors for Incisive Surgical, and Contraline.
Marty holds a Bachelor of Science in Accounting from Marquette University.